OncoSil Medical Limited (ASX:OSL)

Australia flag Australia · Delayed Price · Currency is AUD
0.490
-0.030 (-5.77%)
Apr 29, 2026, 4:10 PM AEST
-75.50%
Market Cap 15.96M
Revenue (ttm) 3.72M
Net Income (ttm) -12.92M
Shares Out 30.70M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 43,233
Average Volume 25,225
Open 0.530
Previous Close 0.520
Day's Range 0.490 - 0.530
52-Week Range 0.455 - 2.090
Beta 1.24
RSI 52.81
Earnings Date May 29, 2026

About OncoSil Medical

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2005
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol OSL
Full Company Profile

Financial Performance

In fiscal year 2025, OncoSil Medical's revenue was 1.54 million, a decrease of -1.92% compared to the previous year's 1.57 million. Losses were -15.10 million, 26.7% more than in 2024.

Financial Statements

News

Oncosil Medical Ltd Extraordinary Shareholders Meeting Transcript

Oncosil Medical Ltd Extraordinary Shareholders Meeting Transcript

6 weeks ago - GuruFocus